The advanced therapeutics company Integra Therapeutics moves its headquarters to the new Advanced Therapies Platform at SJD Barcelona Children's Hospital, both members of CATALONIA.HEALTH. It is the first company to be in this advanced therapies’ centre that occupies 1,280 square meters in the Paediatric Cancer Centre at SJD Hospital. Also, has a research and development area for new therapies, and a manufacturing area for cell therapy, gene therapy and tissue engineering medications.
The new centre is part of a joint immunotherapy platform with Hospital Clínic Barcelona (member of CATALONIA.HEALTH) and is a member of the Catalan advanced therapies network promoted by Biocat, of the Spanish CERTERA and TERAV consortia promoted by the Carlos III Health Institute and of a European consortium to produce CAR-T cells for paediatric oncohematology.
Integra Therapeutics has developed the FiCAT gene-writing platform to develop cell therapies for autoimmune and oncology diseases and gene therapies for rare diseases. The company recently announced a licensing deal with Lithuanian company Caszyme that will lead to FiCAT 2.0, and, also, that the company will receive €10.5 million from the European Commission.
Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics, explains: “We’re very happy to have our headquarters in the new Advanced Therapies Platform at SJD Barcelona Children's Hospital because it is a strategic location and perfect springboard for Integra Therapeutics to continue its growth. FiCAT, our gene-insertion technology, makes it possible to develop safer, more powerful cell therapies with simplified industrial production that will allow for synergies with the production activities of the Advanced Therapies Platform.”.
Related news:
Comments